Kathryn H. Brown
About
Kathryn H. Brown is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Kathryn H. Brown has authored 30 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kathryn H. Brown's work include Radiomics and Machine Learning in Medical Imaging (5 papers), Advanced X-ray and CT Imaging (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Kathryn H. Brown is often cited by papers focused on Radiomics and Machine Learning in Medical Imaging (5 papers), Advanced X-ray and CT Imaging (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Kathryn H. Brown collaborates with scholars based in United Kingdom, United States and Netherlands. Kathryn H. Brown's co-authors include Mireille Cantarini, Yuichiro Ohe, Malcolm Ranson, Pasi A. Jänne, David Planchard, Enriqueta Felip, Paul A. Dickinson, Serban Ghiorghiu, Paul Frewer and Suresh S. Ramalingam and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Kathryn H. Brown
28 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kathryn H. Brown United Kingdom | 15 | 1.8k | 1.4k | 931 | 460 | 169 | 30 | 2.4k | ||
| Panos Fidias United States | 25 | 1.8k 1.1× | 1.7k 1.2× | 925 1.0× | 276 0.6× | 124 0.7× | 58 | 3.0k | ||
| Marcelo Marotti United Kingdom | 14 | 2.7k 1.5× | 2.1k 1.5× | 878 0.9× | 747 1.6× | 106 0.6× | 29 | 3.2k | ||
| Roberta Minari Italy | 25 | 1.7k 1.0× | 1.5k 1.0× | 1.1k 1.2× | 585 1.3× | 171 1.0× | 66 | 2.5k | ||
| Ann M. Mauer United States | 23 | 1.1k 0.7× | 1.3k 0.9× | 908 1.0× | 315 0.7× | 113 0.7× | 69 | 2.4k | ||
| Riyaz Shah United Kingdom | 19 | 3.3k 1.9× | 2.8k 1.9× | 1.1k 1.2× | 708 1.5× | 163 1.0× | 48 | 3.9k | ||
| Maximilian J. Hochmair Austria | 27 | 2.1k 1.2× | 2.2k 1.5× | 731 0.8× | 607 1.3× | 58 0.3× | 215 | 2.9k | ||
| Daniel Haggstrom United States | 8 | 1.5k 0.8× | 1.2k 0.8× | 691 0.7× | 455 1.0× | 135 0.8× | 22 | 1.8k | ||
| Annetta Krebs United States | 8 | 1.9k 1.1× | 2.0k 1.4× | 723 0.8× | 395 0.9× | 48 0.3× | 8 | 2.8k | ||
| V.A. Miller United States | 22 | 1.6k 0.9× | 2.1k 1.5× | 924 1.0× | 508 1.1× | 73 0.4× | 83 | 3.0k | ||
| Kristine Pemberton United Kingdom | 13 | 2.0k 1.1× | 1.6k 1.1× | 490 0.5× | 358 0.8× | 62 0.4× | 14 | 2.3k |
Countries citing papers authored by Kathryn H. Brown
Since
Specialization
Citations
This map shows the geographic impact of Kathryn H. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn H. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn H. Brown more than expected).
Fields of papers citing papers by Kathryn H. Brown
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kathryn H. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn H. Brown. The network helps show where Kathryn H. Brown may publish in the future.
Co-authorship network of co-authors of Kathryn H. Brown
This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn H. Brown. A scholar is included among the top collaborators of Kathryn H. Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn H. Brown. Kathryn H. Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Brown, Kathryn H., Mihaela Ghita, Kevin M. Prise, et al.. (2025). Dose, dose rate and split dose impacts murine skin responses following photon FLASH irradiation. Radiotherapy and Oncology. 212. 111125–111125.
2.
Ghita, Mihaela, Gerard Walls, B. Kerr, et al.. (2025). Preclinical characterisation of changes in cardiac function and circulating biomarkers following differential irradiation of thoracic volumes. Frontiers in Oncology. 15. 1623753–1623753.
3.
Brown, Kathryn H., B. Kerr, Kate Connor, et al.. (2024). A comparative analysis of preclinical computed tomography radiomics using cone-beam and micro-computed tomography scanners. Physics and Imaging in Radiation Oncology. 31. 100615–100615.
4.
Brown, Kathryn H., Mihaela Ghita, B. Kerr, et al.. (2024). Characterisation of quantitative imaging biomarkers for inflammatory and fibrotic radiation-induced lung injuries using preclinical radiomics. Radiotherapy and Oncology. 192. 110106–110106.
5.
Ghita, Mihaela, Kevin Edgar, Kathryn H. Brown, et al.. (2024). Dose-dependent changes in cardiac function, strain and remodelling in a preclinical model of heart base irradiation. Radiotherapy and Oncology. 193. 110113–110113.
6.
Brown, Kathryn H., Sarah Osman, Mihaela Ghita, et al.. (2023). Development and optimisation of a preclinical cone beam computed tomography-based radiomics workflow for radiation oncology research. Physics and Imaging in Radiation Oncology. 26. 100446–100446.
7.
Brown, Kathryn H., Mihaela Ghita, Giuseppe Schettino, Kevin M. Prise, & Karl T. Butterworth. (2020). Evaluation of a Novel Liquid Fiducial Marker, BioXmark®, for Small Animal Image-Guided Radiotherapy Applications. Cancers. 12(5). 1276–1276.
8.
Planchard, David, Kathryn H. Brown, Dong‐Wan Kim, et al.. (2016). Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemotherapy and Pharmacology. 77(4). 767–776.
9.
Jänne, Pasi A., James Chih‐Hsin Yang, Dong‐Wan Kim, et al.. (2015). AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 372(18). 1689–1699.
10.
Hyams, David M., Arlene Chan, Raymond Snyder, et al.. (2013). Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Investigational New Drugs. 31(5). 1345–1354.
11.
Herpen, Carla M.L. van, Ulrik Lassen, Ingrid M.E. Desar, et al.. (2012). Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. Anti-Cancer Drugs. 24(2). 204–211.
12.
Lassen, Ulrik, Wilson H. Miller, Sébastien J. Hotte, et al.. (2012). Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy and Pharmacology. 71(2). 543–549.
13.
Satoh, Taroh, Yasuhide Yamada, Kei Muro, et al.. (2011). Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 69(2). 439–446.
14.
Banerji, Udai, D. Ross Camidge, Henk M.W. Verheul, et al.. (2010). The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer. Clinical Cancer Research. 16(5). 1613–1623.
15.
Fox, Elizabeth, Richard Aplenc, Rochelle Bagatell, et al.. (2010). A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. Journal of Clinical Oncology. 28(35). 5174–5181.
16.
Samtani, Mahesh N., et al.. (2009). Pharmacokinetic and Pharmacodynamic Modeling of Pegylated Thrombopoietin Mimetic Peptide (PEG‐TPOm) After Single Intravenous Dose Administration in Healthy Subjects. The Journal of Clinical Pharmacology. 49(3). 336–350.
17.
Banerji, Udai, D. Ross Camidge, Kathryn H. Brown, et al.. (2008). The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): A phase I trial in patients (pts) with advanced cancer. Journal of Clinical Oncology. 26(15_suppl). 3535–3535.
18.
Register, Thomas C., Cynthia J. Lees, Scott G. Lundeen, et al.. (2007). Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis). American Journal of Obstetrics and Gynecology. 196(1). 75.e1–75.e7.
19.
Mascarello, James T., et al.. (1994). Mosaic triple trisomy in amniocytes from a phenotypically and karyotypically normal fetus. Prenatal Diagnosis. 14(3). 163–165.
20.
Brown, Kathryn H.. (1984). Growth, physique and age at menarche of Mexican American females aged 12 through 17 years residing in San Diego County, California. University Microfilms International eBooks.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Marcelo Marotti Breakdown of academic impact, for papers by Roberta Minari Breakdown of academic impact, for papers by Ann M. Mauer Breakdown of academic impact, for papers by Riyaz Shah Breakdown of academic impact, for papers by Maximilian J. Hochmair Breakdown of academic impact, for papers by Daniel Haggstrom Breakdown of academic impact, for papers by Annetta Krebs Breakdown of academic impact, for papers by V.A. Miller Breakdown of academic impact, for papers by Kristine Pemberton